A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

NCT05153590 · Completed

Last updated 2026-05-28

This study is testing how Saxenda® affects weight loss in adults with obesity or overweight in real-life settings in Switzerland.

Status Completed The study has finished.

Type Observational

Participants 269 people

Who can join Ages 18–74 · all sexes

Timeline Started 2021-12 · est. completion 2022-04

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT05153590 ↗

Description as written by the study sponsor.

The study is investigating weight loss and treatment patterns associated with the use of Saxenda® in adult patients. The aim of the study is to assess the weight loss associated with Saxenda® in patients with obesity or overweight. Saxenda® was prescribed to participants by study doctor independently of this study. The study will last for about 4 months, where the data will be collected from the available medical records. There will be no additional activities expected from participants in the scope of study because it is a chart-review study.

Treatments tested

Saxenda® Drug

Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician. The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups.

Main thing measured	Relative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity or Overweight
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05153590 ↗